Resiquimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Resiquimod Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Resiquimod can convert its Small molecule drug profile and TLR7 x TLR8 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Resiquimod (query alias: Resiquimod) |
|---|---|
| Modality / target | Small molecule drug; TLR7 x TLR8; TLR7 agonists, TLR8 agonists |
| Highest global status | Phase 2 |
| Originator | 3M Co. |
| Active developers | 3M Health Care, Inc., Surge Therapeutics Inc, Galderma International SAS |
The MCP disease footprint includes Actinic Keratosis, Basal Cell Carcinoma, Hepatitis B. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06488118 | Not Applicable | Unknown status | 36 | Primary endpoint not disclosed in English source |
| NCT06450106 | Phase 1 | Recruiting | 18 | Primary endpoint not disclosed in English source |
| NCT06021002 | Not Applicable | Unknown status | 24 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Phase 1/2; n=50; evaluation: Not stated in English source. Reported fields: BLOOD/LYMPHATIC - Other = 0 Pts ; BLOOD/LYMPHATIC - Other = 0 Pts
Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
Phase 2; n=47; evaluation: Not stated in English source. Reported fields: Other (Not Including Serious) Adverse Events = 13 Pts ; Other (Not Including Serious) Adverse Events = 9 Pts
A Randomized, Double-blind, Multi-centre, Placebo-controlled, Parallel-arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA
Phase 2; n=86; evaluation: Not stated in English source. Reported fields: 25th (95% CI) = 169 Day (95%CI, 84.0 - 169.0); 25th (95% CI) = 85 Day (95%CI, 83.0 - 174.0)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Resiquimod addresses Actinic Keratosis, Basal Cell Carcinoma, Hepatitis B. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 13 matched transaction record(s) under the scope “target-level comparable: TLR7 x TLR8.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: TLR7 x TLR8 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-07-01 | BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut | Phase 2 | Financial terms not disclosed |
| 2025-06-16 | Sumitomo Pharma partnered to develop Osaka University 's SA-5 for the treatment of chronic HBV infection | Preclinical | Financial terms not disclosed |
| 2022-05-05 | Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Patent source description not available in English”. The milestone feed surfaced a patent-application signal described as “Topical treatment of arborviral infections”. The milestone feed surfaced a patent-application signal described as “Rescimod prodrug, prodrug nano-micelle and preparation method and application of Rescimod prodrug and prodrug nano-micelle”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
